(P080) Favorable Outcomes Using Radiation Therapy After Chemotherapy in the Management of Primary, Recurrent, and Metastatic Ovarian Cancer

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

The use of RT for primary or recurrent ovarian cancer is well tolerated, with durable rates of FFP. RT with palliative intent achieved high rates of symptom palliation without much additional toxicity. RT should be considered for patients with advanced ovarian cancer.

Carolina E. Fasola, MD, MPH, Daniel S. Kapp, MD, Elizabeth Kidd, MD; Department of Radiation Oncology, Stanford University School of Medicine

PURPOSE: This study aimed to evaluate treatment outcomes and toxicity of radiation therapy (RT) in patients with primary, recurrent, or metastatic ovarian cancer following treatment with chemotherapy.

MATERIALS AND METHODS: We reviewed the medical records of 133 patients with stage I–IV ovarian cancer treated at our institution between 1997 and 2014. Patients underwent the following treatment regimens after initial tumor debulking surgery and chemotherapy: whole-abdominopelvic RT (n = 15), RT at the time of localized recurrence (n = 57), or palliative RT in the metastatic setting (n = 61). Freedom from progression (FFP) and overall survival (OS) were estimated using Kaplan-Meier analysis.

RESULTS: The median follow-up time among all patients was 15.6 months (range: 1–200 mo) and 22.5 months among patients treated with curative intent for primary or recurrent disease. For patients treated with curative intent, the majority had International Federation of Gynecology and Obstetrics (FIGO) stage III disease at initial presentation (65%) with papillary serous histology (47%). A total of 55 (76%) patients had platinum-sensitive disease, and 17 (24%) were considered platinum-resistant. The median prescription RT dose in this cohort of patients was 45.9 Gy (range: 30–57.6 Gy) delivered using three-dimensional (3D) conformal RT (n = 60) or intensity-modulated radiotherapy (IMRT)/ stereotactic body radiotherapy (SBRT) (n = 12). The 2-year FFP and OS rates among this cohort were 84.4% and 63.6%, respectively. The 2-year OS rates for platinum-sensitive disease vs platinum-resistant disease were 65.2% and 35.7%, respectively (P = .02). Predictors of decreased FFP included a diagnosis of primary peritoneal carcinoma (P = .02) and time to RT < 12 months (P = .03). RT was well tolerated, with the majority of patients reporting no acute effects (56%) or developing mild symptoms, such as grade 1 gastrointestinal or urinary toxicity (19%). Late toxicity consisting of small bowel obstruction occurred in seven patients with other risk factors, including previous surgical resections; five (71%) of these patients had received whole-abdominopelvic radiation. For patients with metastatic ovarian cancer treated with palliative intent, the median dose of RT was 30 Gy (range: 10–50.4 Gy), delivered using 3D conformal RT (n = 44) and IMRT/stereotactic radiosurgery (SRS) (n = 17). Symptom palliation was achieved in 96% of cases. Reports of toxicity were low for this cohort of patients, with no grade ≥ 3 toxicity. The 2-year OS for patients treated with palliative intent was 53.8%.

CONCLUSIONS: The use of RT for primary or recurrent ovarian cancer is well tolerated, with durable rates of FFP. RT with palliative intent achieved high rates of symptom palliation without much additional toxicity. RT should be considered for patients with advanced ovarian cancer.

Proceedings of the 97th Annual Meeting of the American Radium Society- americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Related Content